Results 191 to 200 of about 2,458 (200)

Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia

Annals of Hematology, 2017
Laura Orioli, K. Sarti, E. Van Den Neste, D. Maiter   +3 more
openaire   +1 more source

Belinostat/duvelisib

Reactions Weekly
openaire   +1 more source

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Case Medical Research, 2019
openaire   +1 more source

Duvelisib/romidepsin

Reactions Weekly
openaire   +1 more source

A shorter and alternative route to duvelisib: Application in scale-up synthesis

Journal of the Indian Chemical Society
Srinivasa Rao Buddepu, Rapolu Venkateshwarlu, Garbapu Suresh, Kishna Murthy V.R. Moturu, Vidavalur Siddaiah, Manojit Pal   +5 more
openaire   +1 more source

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Case Medical Research, 2019
openaire   +1 more source

A Phase 2 Study of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma.

Case Medical Research, 2019
openaire   +1 more source

EE158 Economic Evaluation of Duvelisib Versus Ofatumumab in Relapsed/Refractory CLL/SLL in Japan

Value in Health
K Shimizu, K Moriwaki, K Morimoto, K Shimozuma   +3 more
openaire   +1 more source

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Case Medical Research, 2019
openaire   +1 more source

0431 Dermatologic adverse events in patients receiving duvelisib single-agent and combination therapies

Journal of Investigative Dermatology
V. Liao, N. Ganesan, S. Dusza, S. Horwitz, A. Moskowitz, S. Geller   +5 more
openaire   +1 more source